Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
A molecular link between the active component of marijuana and Alzheimer's disease pathology.
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
PI(3,5)P2 biosynthesis regulates oligodendrocyte differentiation by intrinsic and extrinsic mechanisms.
Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis.
Multiple sclerosis: an immune or neurodegenerative disorder?
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
4-aminopyridine toxicity: a case report and review of the literature.
CNS myelin wrapping is driven by actin disassembly.
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging.
Treatment of acute transverse myelitis and its early complications.
Laquinimod in multiple sclerosis.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis.
Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.
Imaging outcomes for trials of remyelination in multiple sclerosis.
Immunology 2013
Neuroprotective effect of masitinib in rats with postischemic stroke.
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.

Pages